An Overview of Clinical Studies in the U.S.
RMCTs Show Promise for Patients with Serious and Life-Threatening Conditions
There are nearly 900 active clinical trials in the United States that are exploring the use of regenerative medicine and cell therapies (RMCTs) for patients with serious and life-threatening conditions. Cancer is the most prevalent condition being studied, representing 48 percent of all active clinical studies, followed by musculoskeletal conditions (11 percent), neurological conditions (6 percent), cardiovascular conditions (6 percent), COVID-19 (5 percent), and eye-related conditions (4 percent).
While cancer is the focus of nearly all clinical studies involving T-cells, T-Reg cells, and Natural Killer cells, studies exploring the use of MSCs are focused on musculoskeletal conditions (21 percent), COVID-19 (18 percent), neurological conditions (13 percent), and cardiovascular disease (11 percent).
Similarly, 80% of the clinical trials being performed in the U.S. are either Phase 1 (29%), Phase 1/2 (22%), or Phase 2 (29%) studies. There is one Phase 2/3 clinical trial and one Phase 3 trial being conducted in the U.S.
Clinical Studies are Exploring Promise of Many Different Types of RMCTs
There are many different types of RMCTs. The majority of studies being conducted today explore the use of T-cells and T-Reg cells (46 percent), primarily for cancer. Many clinical studies are also exploring the use of mesenchymal stromal cells (MSCs) (20 percent), gene therapies (14 percent), and natural killer (NK) cells (7 percent) for various conditions. Studies exploring the use of induced pluripotent stem
cells (iPSCs) , bone marrow aspirate concentrate (BMAC), and stromal vascular fraction (SVF) are also being conducted.
Updated as of June 28, 2021